| Background | The anti-CD43 antibody recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation) , identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So, a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Tonsil. Staining Membranous. |
Information sourced from Uniprot.org
![Anti-CD43 antibody [MT1] (STJ16101772)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/600x533/products/152278/347126/STJ16101772_1__21082.1681999395.jpg?c=1 "Anti-CD43 antibody [MT1] (STJ16101772)")